Colorcon Executive and Leadership Team

Subodh Priolkar, the Chief Executive Officer at Colorcon, directs the global strategic vision for pharmaceutical coating systems and functional excipients. Overseeing the entire corporate portfolio, the Chief Executive Officer ensures alignment between technical innovation and market demand. This leadership role involves managing complex supply chains and fostering partnerships with pharmaceutical manufacturers across diverse international territories. By prioritizing research and development, Subodh Priolkar drives the expansion of modified release technologies that define the industry standard. The Chief Executive Officer maintains rigorous quality control standards while scaling operations to meet the evolving needs of the global healthcare sector. Through consistent focus on operational efficiency, the Chief Executive Officer secures long-term growth and maintains the competitive edge of the firm. Priolkar champions a culture of technical excellence, ensuring that every dosage form solution meets the highest regulatory requirements for safety and efficacy in the pharmaceutical manufacturing landscape.

David Graeber, the Vice President & Chief Financial Officer at Colorcon, manages the fiscal health and capital allocation strategies for the organization. Overseeing global financial planning and analysis, the Vice President & Chief Financial Officer ensures that resources support the development of advanced coating systems and functional excipients. This role involves maintaining robust financial controls and providing the data-driven insights necessary for strategic decision-making at the executive level. David Graeber directs the budgeting process to prioritize investments in modified release technologies and technical support infrastructure. By monitoring economic indicators and market volatility, the Vice President & Chief Financial Officer mitigates financial risks while identifying opportunities for sustainable growth. Graeber collaborates with other leaders to ensure that financial performance aligns with the long-term objectives of the firm. This leadership position secures the capital required for ongoing innovation, ensuring that the company maintains the financial stability needed to serve the global pharmaceutical manufacturing sector effectively.

Jen Kain, the Chief Technology Officer at Colorcon, architects the research and development roadmap for advanced coating systems and modified release technologies. Leading the global technical team, the Chief Technology Officer drives the creation of functional excipients that enhance pharmaceutical dosage forms. This role involves collaborating with internal scientists and external partners to push the boundaries of material science and formulation efficiency. Jen Kain ensures that all technological advancements align with the company mission of providing superior technical support to pharmaceutical manufacturers. By overseeing the integration of new laboratory capabilities, the Chief Technology Officer maintains the firm at the forefront of industry innovation. Kain manages the intellectual property portfolio and ensures that all new product developments meet stringent global safety standards. This leadership role requires constant evaluation of emerging manufacturing trends to ensure that the company provides cutting-edge solutions that solve complex formulation hurdles for clients across the global pharmaceutical industry.

Shannon Kelly, the Managing Director (Americas) at Colorcon, oversees all commercial activities and technical support initiatives throughout the North and South American markets. Managing regional growth, the Managing Director (Americas) coordinates with local pharmaceutical manufacturers to implement advanced coating systems and functional excipients. This role involves optimizing regional distribution networks and ensuring that technical service teams provide rapid, effective solutions for complex dosage form challenges. Shannon Kelly drives the adoption of modified release technologies by aligning regional sales strategies with the specific regulatory and manufacturing requirements of the Americas. By fostering strong client relationships, the Managing Director (Americas) ensures that the company remains the preferred partner for pharmaceutical development in the region. Kelly monitors market trends to anticipate shifts in demand, allowing for agile adjustments to regional supply chain strategies. This leadership position directly impacts the overall market penetration and revenue stability of the firm within the Western Hemisphere.